Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves

Article content

• The NEUROFUSE Study is an ongoing 48-week Multicenter, Randomized, evaluator-blinded, Phase 2a study in upper extremity nerve transections comparing NTX-001 adjunctive to standard of care (SOC) to SOC alone.
• In a planned interim analysis of the primary timepoint, NTX-001 demonstrated early and sustained improvement in function and symptoms compared to standard of care.
• The company plans to submit these top-line results for presentation at an upcoming scientific conference in 2024.
• The company plans to meet with the FDA in the first half of 2024 to discuss future late-phase development and the path to approval.